Novel C-terminal HBx truncation (G135) in genotype D1 HBV: predicted effects on oncogenic signaling

Key Points

• The HBx truncation G135 is predicted to disrupt oncogenic signaling pathways.
• This study identifies significant alterations in tumor biomarkers linked to genotype D1 HBV.
• Predictions were made using bioinformatics tools to analyze molecular interactions.
• The findings highlight the need for further investigation into HBV's role in cancer development.